novel
nucleosid
analog
evalu
antirna
viru
activ
rodent
parallel
relat
compound
halfdaili
intraperiton
ip
dose
substanc
administ
h
prior
ip
viru
challeng
protect
major
mice
infect
banzi
encephalomyocard
san
angelo
semliki
forest
virus
dose
mgkgday
compound
mgkgday
also
protect
suckl
rat
infect
intranas
rat
coronaviru
howev
surviv
benefit
afford
treat
mice
infect
intranas
vesicular
stomat
viru
oral
activ
semliki
forest
viru
mice
mgkgday
wherea
report
effect
oral
uninfect
mice
two
compound
induc
similar
amount
interferon
follow
ip
inject
interferon
induc
oral
treatment
fifti
percent
acut
lethal
dose
uninfect
mice
treat
ip
halfdaili
dose
one
day
mortal
dose
mgkgday
respect
daili
ip
treatment
day
substanc
mgkgday
show
lethal
two
substanc
toxic
virtu
reduc
toxic
oral
bioavail
appear
greatest
clinic
potenti
interferoninduc
antivir
agent
nucleosid
biolog
respons
modifi
synthes
inhibit
mani
rna
dna
virus
mice
rat
smee
et
al
compound
guanosin
analogu
activ
virtu
interferon
induct
although
immun
compon
bcell
natur
killer
cell
macrophag
also
stimul
smee
et
al
recent
show
ribosyl
moieti
replac
variou
alkyl
side
chain
mani
result
compound
exhibit
antivir
activ
mice
michael
et
al
fig
one
first
interferoninduc
nucleosid
investig
antivir
activ
nagahara
et
al
smee
et
al
smee
et
al
shown
activ
intraperiton
ip
oral
administr
subsequ
found
activ
ip
oral
rout
smee
et
al
given
short
one
two
day
durat
howev
daili
dose
week
fatal
mice
continu
search
oral
activ
compound
minim
toxic
fig
synthes
report
describ
antivir
activ
compar
sever
viru
infect
vivo
includ
data
oral
activ
semliki
forest
virusinfect
mice
abil
induc
interferon
present
toxic
compar
synthes
ramasami
et
al
follow
procedur
stir
solut
deriv
g
mmol
dri
dimethylformamid
dmf
ml
ad
nchlorosuccinimid
g
mmol
dmf
ml
period
mixtur
stir
room
temperatur
h
evapor
dryness
residu
purifi
silica
gel
column
cm
use
aceton
gradient
fraction
contain
elut
first
pool
evapor
dryness
residu
crystal
mixtur
hexan
yield
g
product
product
isol
subsequ
fraction
foam
identifi
df
smee
et
al
antivir
research
g
prepar
solut
g
mmol
methanolammonia
ml
satur
stir
room
temperatur
h
pressur
bottl
reaction
mixtur
cool
bottl
open
solvent
evapor
dryness
residu
purifi
silica
gel
column
x
cm
use
methanol
gradient
homogen
fraction
pool
evapor
dryness
residu
crystal
mixtur
acetonemethanol
yield
g
yield
overal
yield
entir
reaction
scheme
puriti
nuclear
magnet
reson
spectroscopi
use
identifi
character
product
synthes
use
publish
method
ramasami
et
al
nagahara
et
al
pure
compound
dissolv
sodium
bicarbon
ph
achiev
aqueou
solubl
bicarbon
serv
placebo
control
anim
experi
banzi
viru
strain
flaviviru
encephalomyocard
viru
emc
strain
picornaviru
san
angelo
viru
bunyaviru
semliki
forest
viru
origin
strain
togaviru
rat
coronaviru
strain
vesicular
stomat
viru
indiana
strain
rhabdoviru
obtain
american
type
cultur
collect
rockvil
md
swiss
webster
femal
mice
g
pregnant
lewi
rat
charl
river
lab
wilmington
rna
virus
chosen
activ
virus
smee
et
al
smee
et
al
smee
et
al
method
infect
mice
suckl
rat
virus
report
previous
smee
et
al
smee
et
al
briefli
intraperiton
infect
banzi
encephalomyocard
san
angelo
semliki
forest
virus
made
infect
rat
coronaviru
vesicular
stomat
viru
done
intranas
rout
approxim
ten
lethal
dose
given
anim
pretreat
regimen
employ
found
effect
relat
compound
smee
et
al
increas
survivor
number
evalu
twotail
fisher
exact
test
mean
surviv
time
increas
statist
analyz
twotail
mannwhitney
u
test
test
abl
evalu
result
group
size
anim
die
fewer
three
interferon
induct
studi
toxic
determin
conduct
uninfect
mice
serum
collect
mice
hour
ip
treatment
compound
assay
interferon
cell
infect
hour
later
vesicular
stomat
viru
describ
previous
smee
et
al
four
mice
per
group
use
sera
assay
separ
interferon
content
acut
day
treatment
chronic
day
treatment
lethal
toxic
studi
perform
use
ip
treat
mice
per
group
respect
result
ip
pretreat
surviv
mice
rat
infect
variou
rna
virus
present
tabl
within
limit
biolog
variabl
compound
approxim
equal
potenc
differ
virus
activ
dosag
rang
two
compound
similar
report
previous
smee
et
al
smee
et
al
smee
et
al
unabl
prevent
mortal
delay
time
death
mice
infect
vesicular
stomat
viru
data
shown
previous
report
smee
et
al
placebo
placebo
administr
smee
et
al
smee
et
al
signific
protect
achiev
dose
mgkgday
ip
rout
lesser
extent
mgkgday
oral
administr
degre
oral
antivir
potenc
similar
report
smee
et
al
certain
kind
virus
suscept
treatment
interferoninduc
agent
rodent
model
smee
et
al
profil
inhibit
rna
virus
report
agreement
former
studi
activ
banzi
san
angelo
semliki
forest
rat
coronavirus
effect
encephalomyocard
viru
compar
present
result
smee
et
al
appear
similar
term
potenc
efficaci
rna
virus
test
given
ip
rout
sinc
previou
work
shown
interferon
induct
import
antivir
activ
type
nucleosid
analogu
smee
et
al
smee
et
al
abil
induc
interferon
assess
parallel
result
mgkg
ip
compar
favor
previous
report
smee
et
al
indic
interferon
unit
per
ml
present
serum
h
respect
similarli
serum
treat
mice
mgkg
ip
contain
unit
interferon
h
respect
base
upon
biolog
variat
signific
differ
amount
interferon
induc
two
nucleosid
oral
treatment
mgkg
interferon
unitsml
detect
serum
h
respect
interferon
detect
serum
follow
oral
treatment
may
explain
exhibit
oral
antivir
activ
mice
acut
chronic
toxic
compar
uninfect
mice
anim
treat
ip
halfdaili
dose
one
day
high
dose
compound
advers
affect
lethal
dose
mgkgday
respect
afflict
mice
die
day
treatment
contrast
mortal
observ
mice
treat
mg
per
kgday
anim
given
high
mgkgday
lost
averag
g
within
twoday
period
treatment
compar
averag
weight
gain
g
placebo
group
suggest
advers
effect
chronic
mgkgday
treatment
daili
day
result
mortal
compar
mortal
treat
mice
began
die
one
week
treatment
result
indic
less
toxic
mice
evid
unpublish
studi
conduct
institut
suggest
substitut
introduc
reduc
abil
compound
undergo
phosphoryl
reduc
potenti
toxic
phosphoryl
form
nucleosid
mono
di
triphosph
gener
respons
intraceuular
toxic
due
interact
cellular
enzym
mode
antivir
action
like
interferon
induct
sinc
interferon
induc
treat
mice
use
antiinterferon
serum
previous
abl
abolish
antivir
activ
two
unrel
rna
virus
mice
smee
et
al
smee
et
al
other
also
demonstr
import
chemicallyinduc
interferon
protect
virusinfect
anim
kunder
et
al
morahan
et
al
sarzotti
et
al
also
markedli
stimul
murin
bcell
blastogenesi
nagahara
et
al
manuscript
submit
effect
probabl
contribut
antivir
activ
result
studi
perform
indic
type
compound
gener
given
earli
cours
infect
order
exert
antivir
effect
sinc
et
al
smee
et
al
except
punta
toro
viru
infect
could
treat
late
h
viru
challeng
still
curabl
smee
et
al
stringfellow
et
al
determin
mani
viru
infect
suppress
abil
mice
produc
interferon
respons
chemic
induc
induc
administ
sever
hour
viru
inocul
reason
pretreat
given
soon
infect
almost
alway
warrant
done
present
studi
oral
bioavail
desir
properti
drug
due
eas
reduc
cost
administr
first
evalu
repres
improv
exhibit
oral
antivir
activ
vivo
smee
et
al
wherea
sinc
et
al
sinc
et
al
toxic
effect
repeat
dose
prove
undesir
characterist
howev
substitut
chlorin
atom
molecul
found
much
less
toxic
yet
equal
activ
viru
infect
vivo
recent
show
substitut
ribosyl
portion
molecul
alkyl
group
could
made
without
subsequ
loss
ip
antivir
activ
michael
et
al
howev
alkyl
compound
oral
activ
fact
relat
compound
synthes
evalu
date
oral
bioactiv
promis
two
orallyact
interferoninduc
antivir
due
decreas
toxic
